医药前沿
醫藥前沿
의약전연
YIAYAO QIANYAN
2012年
35期
15-16
,共2页
曲美他嗪%风湿性心脏病%慢性心衰%疗效
麯美他嗪%風濕性心髒病%慢性心衰%療效
곡미타진%풍습성심장병%만성심쇠%료효
trimetazidine%rheumatic heart disease%chronic heart failure%clinical efficacy
目的研究曲美他嗪治疗风湿性心脏病慢性心衰(CHF)患者的临床效果.方法选自2010年2月-2012年2月于我院就诊的82例 CHF 患者,随机分为两组,对照组40例,仅采用常规的抗心衰药物治疗,观察组42例,曲美他嗪辅助常规治疗,12周后比较两组患者 LVEF、LVEDD、心功能分级、CI 疗效等指标.结果观察组 LVEF、LVEDD、心功能分级改善效果明显优于对照组(P<0.01),而且临床 CI 总有效率85.71%显著高于对照组62.50%(P<0.05).结论曲美他嗪辅助常规药物治疗风湿性心脏病慢性心衰患者,可有效改善心脏收缩功能,疗效显著,安全可靠,值得临床推广应用.
目的研究麯美他嗪治療風濕性心髒病慢性心衰(CHF)患者的臨床效果.方法選自2010年2月-2012年2月于我院就診的82例 CHF 患者,隨機分為兩組,對照組40例,僅採用常規的抗心衰藥物治療,觀察組42例,麯美他嗪輔助常規治療,12週後比較兩組患者 LVEF、LVEDD、心功能分級、CI 療效等指標.結果觀察組 LVEF、LVEDD、心功能分級改善效果明顯優于對照組(P<0.01),而且臨床 CI 總有效率85.71%顯著高于對照組62.50%(P<0.05).結論麯美他嗪輔助常規藥物治療風濕性心髒病慢性心衰患者,可有效改善心髒收縮功能,療效顯著,安全可靠,值得臨床推廣應用.
목적연구곡미타진치료풍습성심장병만성심쇠(CHF)환자적림상효과.방법선자2010년2월-2012년2월우아원취진적82례 CHF 환자,수궤분위량조,대조조40례,부채용상규적항심쇠약물치료,관찰조42례,곡미타진보조상규치료,12주후비교량조환자 LVEF、LVEDD、심공능분급、CI 료효등지표.결과관찰조 LVEF、LVEDD、심공능분급개선효과명현우우대조조(P<0.01),이차림상 CI 총유효솔85.71%현저고우대조조62.50%(P<0.05).결론곡미타진보조상규약물치료풍습성심장병만성심쇠환자,가유효개선심장수축공능,료효현저,안전가고,치득림상추엄응용.
Objective: To investigate clinical efficacy of treatment of rheumatic heart disease with chronic heart failure (CHF)by trimetazidine. Methods: 82 patients with CHF in our hospital from February 2010 to February 2012 were divided into the control group(40),treated by conventional anti-heart failure medication,and the observation group(42), treated by trimetazidine. After 12 weeks ,LVEF ,LVEDD,heart function classification and CI efficacy of patients were compared .Results: The LVEF, LVEDD and heart function of observation group were significantly better than the control group(P<0.01) , and the total effective rate of clinical CI (85.71% )was significantly higher than 62.50% (P<0.05).Conclusion:trimetazidine auxiliary conventional drug treatment of rheumatic heart disease in patients with chronic heart failure , can be effective in improving cardiac contractile function , a significant effect , safe and reliable.
